Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
ITD-1
Cat. No.:
OB0225LY-0213
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
ITD-1 is a highly selective TGFβ pathway inhibitor.
Synonym:
1099644-42-4; ITD 1; Ethyl 2,7,7-trimethyl-5-oxo-4-(4-phenylphenyl)-1,4,6,8-tetrahydroquinoline-3-carboxylate; ITD1; (+)-ITD 1; Ethyl 4-([1,1'-biphenyl]-4-yl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate; 4-[1,1'-Biphenyl]-4-yl-1,4,5,6,7,8-hexahydro-2,7,7-trimethyl-5-oxo-3-quinolinecarboxylic acid ethyl ester; Ethyl 4-(biphenyl-4-yl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate
CAS No.:
1099644-42-4
Compound CID:
44135961
Formula:
C27H29NO3
Formula Weight:
415.52
Specification
Relative Density:
1.18 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
ITD-1 can be used in the study of disease pathomechanisms or play an important role in high-throughput screening.
Library Information
Targets:
TGF-β receptor family
Receptors:
Type II TGF-b receptor
Pathways:
Stem cells; TGF-beta/Smad signaling
Plate Number:
AOCL-3
Plate Location:
f7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
8.31 mg/mL; 20 mM
Ethanol Max Solubility:
4.16 mg/mL; 10 mM
